AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.

Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely und...

Full description

Saved in:
Bibliographic Details
Main Authors: David B Rosen, Kimberly H Harrington, James A Cordeiro, Ling Y Leung, Santosh Putta, Norman Lacayo, George S Laszlo, Chelsea J Gudgeon, Donna E Hogge, Rachael E Hawtin, Alessandra Cesano, Roland B Walter
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2013
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/cdee93bca07145d3b4ee0e020e486f40
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items